drugset / Trial / NCT01149681
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, Phase II Clinical Trial of Aplidin® (plitidepsin) in Patients with Primary Myelofibrosis and post polycythemia vera/essential thrombocythemia (Post-PV/ET) Myelofibrosis.
Timeline
- Start
- 2010-07
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plitidepsin | Peptide | 5 mg/m2 | Intravenous |